simeprevir - Articles and news items

Janssen Pharmaceuticals Logo

OLYSIO™ (simeprevir) receives marketing authorisation in the European Union for the treatment of adults with hepatitis C genotype 1 and 4 infection

Industry news, News / 19 May 2014 / Janssen Pharmaceutical Companies

Janssen-Cilag International NV today announced that its next generation protease inhibitor OLYSIOTM (simeprevir) has been granted marketing authorisation by the European Commission for the treatment of adults with genotype 1 and 4 chronic hepatitis C…

Janssen Pharmaceuticals Logo

Janssen announces collaboration with Vertex on phase 2 study

Industry news, News / 5 November 2012 /

To investigate an all-oral regimen of simeprevir (Tmc435) and Vx-135 for treatment of hepatitis C…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...